| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
| Trovagene Rebrands as Cardiff Oncology, Promotes Longtime Exec to CEO | Sarah de Crescenzo | 05/07/20 | San Diego |
| Ventus Launches With $60M to Shine Light on Innate Immune System Drugs | Frank Vinluan | 05/06/20 | Boston |
| Encouraging Signals for New Cancer Cell Therapy Strategies | Mandy Jackson | 05/06/20 | National |
| Kura Narrows Pipeline After Strategic Review Prompted by COVID-19 | Sarah de Crescenzo | 05/05/20 | San Diego |
| Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More | Sarah de Crescenzo | 05/01/20 | National |
| Podcast: How San Diego is Building a Biotech Ecosystem – Genomics & Precision Medicine Experts Weigh in | Editors | 04/30/20 | National |
| Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill | Sarah de Crescenzo | 04/27/20 | San Diego |
| Erasca Lands $200M Mega-Round to Move Cancer Programs to the Clinic | Sarah de Crescenzo | 04/27/20 | San Diego |
| Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More | Frank Vinluan | 04/24/20 | National |
| Synthorx’s Shawver Joins Silverback Therapeutics as New Top Exec | Sarah de Crescenzo | 04/22/20 | Seattle |
| Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19) | Frank Vinluan | 04/22/20 | National |
| New COVID-19 Special Reports Explore Clinical Research During the Pandemic | Editors | 04/21/20 | Boston |
| COVID-19 Vax Efforts Aim to Balance Speed, Efficacy in Race to Market | Sarah de Crescenzo | 04/17/20 | National |
| Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More | Sarah de Crescenzo | 04/17/20 | National |
| With Harvard Tech and $5M, PIC Therapeutics Takes Aim at Cancer | Frank Vinluan | 04/15/20 | Boston |
| GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year | Frank Vinluan | 04/14/20 | National |
| Arcturus Poised to Move Liver Drug, COVID-19 Vaccine Into Clinic | Sarah de Crescenzo | 04/14/20 | San Diego |
| Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More | Frank Vinluan | 04/10/20 | National |
| Pfizer, BioNTech Say mRNA COVID-19 Vaccine Trials May Start This Month | Frank Vinluan | 04/09/20 | National |
| Organovo Future Unclear After Shareholders Reject Tarveda Merger | Sarah de Crescenzo | 04/08/20 | San Diego |
| Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics | Frank Vinluan | 04/08/20 | Boston |
| Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers | Sarah de Crescenzo | 04/08/20 | National |
| Xconomy Releases Coronavirus Special Report on Containing the Pandemic Through Innovation & Investment | Editors | 04/06/20 | Boston |
| Dynacure Adds $55M As RNA-Targeted Muscle Disorder Drug Enters Clinic | Sarah de Crescenzo | 04/03/20 | Boston |
| Fate Inks $100M Deal With Janssen for Stem Cell-Derived Cancer Therapies | Sarah de Crescenzo | 04/03/20 | San Diego |
| Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More | Sarah de Crescenzo | 04/03/20 | National |
| Flagship Adds $1.1B for New Meds, More AI, & “Health Security” | Sarah de Crescenzo | 04/02/20 | National |
| Aspen Neuro Adds $70M to Test Parkinson’s Cell Therapy in the Clinic | Sarah de Crescenzo | 04/01/20 | San Diego |
| A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy | Frank Vinluan | 03/31/20 | Raleigh Durham |
